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Background: Alcoholic Hepatitis (AH) is the most severe form of Alcoholic Liver Disease 
(ALD) and current therapies are not fully effective. Targeted therapies are urgently needed. 
AKR1B10 was recently shown to be overexpressed in patients with AH. 
Objectives: To analyze the expression of AKR1B10, an aldose reductase, through a translational 
approach in order to better understand the potential for aldose reductase as a novel target of 
therapy in AH. 
Methods: RNA was extracted from human tissue samples from patients with various liver 
diseases, animal models of fibrosis and alcoholic liver disease, and cultured Hepatic Stellate Cell 
(HSC) lines stimulated with proinflammatory, profibrogenic, and AKR1B10 treatments, and the 
samples were quantified using qPCR analysis. 
Results: Human samples showed nearly a 100-fold increase of AKR1B10 expression in patients 
with AH. An animal model of liver fibrosis showed a small increase in Akr1b8 (AKR1B10 mouse 
analogue) expression. HSCs did not show any noticeable increase in expression of AKR1B10 
regardless of treatment, and did not show any noticeable increase in expression of 
proinflammatory or profibrogenic genes when treated with AKR1B10. 
Conclusion: The increased expression of AKR1B10 and its mouse analogue, while present in 
patients with AH and fibrotic mice, respectively, may not be mediated by HSCs. Further studies 
are needed to better understand location and nature of overexpression. 
INTRODUCTION 
Alcoholic Liver Disease (ALD) is a major etiology of end-stage liver disease, accounting for 
40% of mortality from cirrhosis
1
 and a higher annual mortality than for hepatitis C virus (HCV)
2
. 
The natural history of ALD includes the development of steatosis in 80-90% of heavy drinkers, 
followed by development of more severe and symptomatic forms of ALD in 20-40% of patients 
with steatosis
3
. Alcoholic Hepatitis (AH) is a severe acute-on-chronic disease that is 
characterized by an inflammation of the liver that results in liver injury, and severe cases have a 
mortality rate of approximately 30-50%
4
. Unfortunately, the pathogenesis of this disease is not 
well characterized. The most effective therapy for patients with AH is corticosteroid therapy, 
which was initially developed over 40 years ago
3-6
, and while it has shown to be effective in 
increasing the survival of some patients with AH, not all patients respond well and the mortality 
rate remains high
4,7
. The development of new therapeutic strategies has been made difficult due 
to poor knowledge of involved mechanisms and lack of appropriate animal models
8
. It is thus 
important to look for new targets of therapy. 
Several promising new targets have been identified, including pro-inflammatory 
cytokines, chemokines and their receptors, anti-inflammatory molecules
8,9
, and tumor necrosis 
factors
10
. Interestingly, a transcriptome analysis of patients with AH, previously performed in 
our group, yielded a 432-fold overexpression of aldo-keto Reductase Family 1, member B10 
(AKR1B10)
10
, known as aldose reductase, which does not have any known role in AH. 
AKR1B10 is related to the aldose reductase AKR1B1, which reduces glucose to sorbitol as part 
of the Polyol pathway and is expressed ubiquitously in human tissues
11
. The Polyol pathway is 
involved in secondary diabetic complications such as retinopathy
12
, neuropathy
13
, and 
nephropathy
14
. AKR1B10 has a similar function, but is primarily expressed in the small intestine 
and colon with little expression in the liver under normal conditions and metabolizes retinals, 
carbonyls, and several lipid substrates, which may play a crucial role in promoting 
carcinogenesis
11,15
. Additionally, aldose reductase has been shown to be highly expressed in 
liver
16
, colon
17
, and prostate cancer
18
, among others
19
. Consequently, the overexpression of 
AKR1B10 in AH patients may play an important role in ALD disease progression and the 
mortality and morbidity associated with AH. It is unknown through which hepatic cell the 
AKR1B10 may be playing a role in AH and the nature of the pathway of expression in patients 
with AH.  
In chronic liver injury, Hepatic Stellate Cells (HSCs) differentiate from a fat-storing 
phenotype to a myofibroblast-like phenotype that secretes fibroblastic cell markers and 
extracellular matrix that is indicated in fibrosis and cirrhosis
20
. Patients with ALD generally have 
activated HSCs. Alcohol consumption enhances gut permeability, leading to a translocation of 
bacterial derived liposaccharide (LPS) which primarily stimulates Kupffer cells (and to a certain 
extent, HSCs) in the liver, causing inflammation and fibrogenesis
8,21
. Platelet-Derived Growth 
Factor (PDGF), produced by Kupffer cells and Biliary cells, is the main mitogen for activated 
HSCs, directly promoting fibrogenesis
22
. Stimulation of HSCs by the proinflammatory LPS and 
LPS-derived cytokines from Kupffer cells, and profibrogenic PDGF lead to differential gene 
expression in HSCs for various functions related to fibrosis. It is therefore feasible that an 
overexpression of AKR1B10 would be seen in HSCs, one of the primary damage response cells, 
and that AKR1B10 expression would be differentially mediated by LPS and PDGF. 
In the present study, we explored the potential role of AKR1B10 as a therapeutic target 
for patients with AH. We investigated the expression of AKR1B10 in human samples, an animal 
model, and cell culture of HSC cell lines, and we sought to better characterize the location and 
pathway of the overexpression of AKR1B10 in order to lead to novel therapies for AH. 
METHODS 
Patients with Alcoholic Hepatitis (AH) and selection of normal control livers. 
The data that was collected was derived from the following methods performed by the 
laboratory. Patients admitted to the Liver Unit, Hospital Clínic of Barcelona with clinical, 
analytical and histological features of AH from 2007 to 2010 were prospectively included in the 
study
7,23,24
. The inclusion criteria have been described in a similar study
10
. All patients had 
histological diagnosis of AH (n = 34). Patients with hepatocellular carcinoma or any other 
potential cause of liver disease were excluded from the study. Liver biopsy was obtained using a 
transjugular approach. As controls, fragments of normal liver tissue (n = 6) were obtained from 
optimal cadaveric liver donors (n = 3) or resection of liver metastases (n = 3) as described in 
detail in a similar study.
10
 All liver specimens were analyzed by an expert pathologist and a part 
of the biopsy was submerged into a RNA stabilization solution (RNAlater, Ambion, Austin, 
Texas, USA). The protocol was approved by the Ethics Committee of the Hospital Clinic and all 
patients gave informed consent.  
Mouse models 
The data that was collected was derived from the following methods performed by the 
laboratory. Hepatic fibrosis was induced in male C57BL/6J mice (Bar Harbor, ME, USA) 
following administration of carbon tetrachloride (CCl4) (Sigma-Aldrich, St Louis, MO, USA) 
injected intraperitoneally at a dose of 0.5 ml/kg, 12.5%  diluted in olive oil, twice a week for four 
weeks, CCl4 (Sigma-Aldrich). Control mice were given olive oil at the same dose. 
Alcoholic liver disease was induced in male male C57BL/6J mice by administering a high-fat 
liquid diet (HFD) containing ethanol. The dose of alcohol started at 5 g/kg/day and 
the concentration of alcohol gradually increased until the total dose of alcohol administered 
reached up to 20 g/kg/day. Control mice were given high-fat liquid diet without ethanol. 
Each group included at least 3 mice. Mice were housed in temperature and humidity-
controlled rooms and kept on a 12-hour light/dark cycle. Mice were sacrificed and collection of 
liver and blood samples was performed. All experimental procedures were reviewed and 
approved by The University of North Carolina at Chapel Hill Institutional Animal Care and Use 
Committee. 
Cell Cultures 
To study  AKR1B10 production and biological effects, LX-2 cells (from Scott L. Friedman, 
Mount Sinai Hospital, New York, NY, USA), a human HSC line
25
, were serum starved for 24 h 
and then incubated with LPS 1 µg/mL (Sigma-Aldrich), PDGF 20 ng/mL (Sigma-Aldrich), and 
recombinant AKR1B10 10 ng/mL, 100 ng/mL, and 1 µg/mL (Novus Biologicals, Littleton, CO, 
USA) for 20 h. Fetal Bovine Serum (FBS) 20%/mL (Sigma-Aldrich) was used as a control.  
RNA Isolation and PCR Analysis 
RNA was isolated from liver tissues, animal models, and cells using Trizol and the 
manufacturer’s protocol (Invitrogen, Carlsbad, CA, USA). Two thousand nanograms of RNA 
were retrotranscribed using a high-capacity complementary DNA reverse-transcription kit 
(Applied Biosystems, Foster City, CA, USA) and complementary DNA (cDNA) were then 
amplified using Taqman Technology (Applied Biosystems) in a final PCR volume of 10 µL 
using a StepOnePlus
TM
 Real-Time PCR System (Applied Biosystems) and various Assay-on-
Demand probes and primers were used (Applied Biosystems).  For human and animal model 
samples, primer-probe pairs for AKR1B10 and AKR1B8 were utilized, respectively. For cell 
culture samples, primer-probe pairs for COL1A1, ICAM1, AKR1B10, TIMP1, IL6, CCL2, 
MMP2, ACTA2, and IL8 were used. However, only the primer-probe pairs for COL1A1, 
ICAM1, AKR1B10, and TIMP1 were analyzed due to sample integrity problems with other 
assessed target genes. Results were normalized to 18s rRNA expression (housekeeping gene). 
The gene expression values were calculated based on the ΔΔCt method and the results were 
expressed as 2
-ΔΔCt
 referred to as fold increase compared with the mean expression quantified on 
normal livers. 
Statistical Analysis 
Results of quantitative variables are expressed as mean plus standard error unless otherwise 
specified. The differences between groups were analyzed using non-parametric tests (Mann-
Whitney U test) for continuous variables. Statistical analysis was performed using SPSS version 
22 (SPSS Inc.,Chicago, IL, USA).  
   
 
 
 
 
 
 
RESULTS 
Patients with AH show increased AKR1B10 hepatic expression 
AKR1B10 was previously identified as the most upregulated hepatic gene in patients with AH
10
. 
To confirm this previous result, we analyzed previous laboratory data on hepatic AKR1B10 
expression in a cohort of patients with AH from a transjugular biopsy by real time qPCR 
analysis. The results confirmed marked upregulation of AKR1B10 in patients with AH compared 
with normal liver and other liver diseases with a 99-fold overexpression of AKR1B10 in patients 
with AH (Figure 1). 
 
Figure 1. AKR1B10 gene expression in  patients with various liver diseases. (*p<0.001 
compared to control and all other studied diseases.) 
AKR1B10 is overexpressed in fibrosis animal models 
There are no animal models that fully characterize the pathogenesis of AH in human patients
8
. 
However, we looked at previously derived laboratory data from CCl4-induced fibrotic liver 
injury in mice as well as an alcohol animal model. We investigated the known mouse analogue 
for AKR1B10, Akr1b8
26
. While the high fat diet plus alcohol administration animal model did not 
show a significant increase in Akr1b8 expression, the CCl4-induced fibrosis animal model 
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showed a significant expression of Akr1b8 over the control (Figure 2). Because HSCs are the 
primary cells involved in fibrosis development
20
 and Akr1b8 is overexpressed in a fibrotic 
animal model, HSCs could be a likely cell source of hepatic AKR1B10 seen in the 
Transcriptome analysis. 
 
Figure 2. Akr1b8 expression in animal models of liver injury. (A) Hepatic Akr1b8 gene 
expression in mice treated with CCl4 (n=3). (*p<0.05 compared with olive oil control). (B) 
Hepatic Akr1b8 gene expression in HFD mice treated with alcohol (n=4). Abbreviation n.s. = not 
significant. 
Proinflammatory and profibrogenic effects on AKR1B10 expression in HSCs 
As expression of AKR1B10 in the liver was found to be significantly higher in AH patients, and 
as HSCs play a key role in the development of liver fibrosis in the during liver injury
8
, we next 
investigated the potential of HSCs to synthesize AKR1B10 and its biological effects on these 
cells. We used several mediators known to play a role in ALD and typically present in the AH 
microenvironment, and investigated whether they induced AKR1B10 expression in human HSC 
cell lines. However, incubation of HSCs (LX-2) with LPS and PDGF did not show a significant 
increase in AKR1B10 levels (Figure 2A). In addition, to investigate the biological effects of 
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AKR1B10 on HSCs, cells were incubated with recombinant AKR1B10, and this similarly did 
not induce the expression of proinflammatory or profibrogenic genes in HSC (Figure 2B).
  
 
 
 
Figure 3. Expression of various genes in human HSC cell lines. (A) Expression of AKR1B10 in 
cultured cells treated with PDGF and LPS. (B) Expression of COL1A1 (profibrogenic), ICAM1 
(proinflammatory), and TIMP1 (profibrogenic) in cultured cells treated with various 
concentrations of recombinant AKR1B10. Abbreviation n.s. = not significant. 
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DISCUSSION 
AH is an acute-on-chronic liver disease that is responsible for much of the morbidity and 
mortality seen in patients with ALD, and is characterized by hepatic inflammation, fibrosis, and 
damage. It is therefore of great importance to identify the key pathways and molecules of the 
disease in order to produce novel and effective therapies. In the present study, we investigated 
the potential role of AKR1B10 as a target for therapies in patients with AH. We performed 
qPCR analyses of human liver biopsies of patients with various liver diseases and of animal 
models of fibrotic and alcohol-supplemented mice. Furthermore, we conducted and analyzed 
tissue culture experiments of HSC cell lines to understand the location and pathway of 
expression of AKR1B10. While the results of the human and animal model samples agreed with 
transcriptome analysis referenced above and suggested the implication of HSCs, the tissue 
culture experiments dismissed this hypothesis, and the mechanism of overexpression could not 
be determined.  
 The results suggest that overexpression of AKR1B10 in patients with AH may not be 
linked to HSCs directly and may be present in other cells of the liver.  While there was a 99-fold 
overexpression of AKR1B10 in patients with AH and the animal models suggested a fibrosis-
producing cell such as HSCs, an increased expression of AKR1B10 could not be reproduced in 
HSC cell lines.  
 There were several limitations to the present study. The major limitation to the animal 
studies is the lack of a proper animal model that can reproduce key pathophysiological features 
of AH
8
. We used data from a study in the laboratory regarding the use of the hepatotoxic CCl4 
which is known to adequately reproduce liver fibrosis and cirrhosis in mice
27
.While we observed  
a 1.5-fold increase in expression of Akr1b8 (p < 0.05) in this model, this result may not be fully 
indicative of the expression of AKR1B10 in AH patients, and the sample size (n = 3) was very 
small. Additionally, the study was limited to gene expression analysis and did not include protein 
analysis that could confirm the results of the qPCR gene expression analysis. While supernatant 
was collected from the cell culture studies, time and resource constraints prevented the analysis 
of the samples.  
 Future studies could examine other liver cells that may be the location of the 
overexpression of AKR1B10 in patients with AH. Potentially, AKR1B10 could be upregulated in 
hepatocytes instead of HSCs. Several pathways have been studied regarding the potential fibrosis 
resulting from improper hepatocyte functioning, such as the activation of HSCs by signals 
derived from hepatocyte apoptosis
28
. The HepG2 human hepatocellular carcinoma cell line could 
be employed to explore potential AKR1B10 overexpression in hepatocytes
29
. Additionally, Liver 
Progenitor Cells (LPCs) have been shown to correlate well with fibrotic liver damage and are 
strong prognostic markers for short-term mortality in patients with AH
30,31
. Future studies could 
assess potential AKR1B10 overexpression in LPCs and hepatocytes by using a similar approach 
as the present work. Finally, further work to assess sorbitol accumulation in human samples 
could help elucidate the molecular function of aldose reductase in the liver during AH 
pathogenesis.
32
 
 A better understanding of the role of various factors in the development and progression 
of AH is of the utmost importance in order to develop novel therapies. The overexpression of 
aldose reductase in patients with AH is poorly understood and could play an important role in the 
disease. Our present study confirms the overexpression of AKR1B10 in AH and suggests that it 
may be linked to cells other than HSCs. Future studies will be needed to explore the role of 
AKR1B10 in AH.  
CONCLUSION 
We confirmed AKR1B10 is overexpressed in patients with AH and observed an analogous 
overexpression in a fibrotic animal model but could not reproduce findings in HSCs. We suggest 
that the expression of the gene is not linked to HSCs and may be found in other cells such as 
Hepatocytes or LPCs.  
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